Ipamorelin

RESEARCH PEPTIDES · GLOSSARY ENTRY

Ipamorelin

A selective growth-hormone-releasing peptide (GHRP) — stimulates GH release without significantly affecting cortisol or prolactin, unlike older GHRPs.

Why it matters

Ipamorelin is a pentapeptide agonist at the ghrelin receptor. The selectivity for GH release (without cortisol or prolactin spikes) makes it preferred over older GHRPs like GHRP-2 and GHRP-6 in research peptide use. Combined with a GHRH analogue (CJC-1295) the GH release is synergistic.

In practice

Typical research protocols use 200–300mcg subcutaneously two or three times daily. Side effects are typically minimal at modest doses.

Common confusion

Ipamorelin is not FDA-approved for any human indication despite its widespread research-peptide market presence.

RELATED TERMS
SOURCES

    This glossary entry is editorial content reviewed against primary sources. It is not medical advice. See our Editorial Policy.

    Scroll to Top

    Disclaimer: Alternative Pharm Press is an independent editorial publication and brand directory; we do not sell, manufacture, or ship any products. The statements and products referenced on this site have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Content is provided for general informational and educational purposes only and is not medical, legal, or professional advice. Always consult a licensed healthcare provider before using kratom, cannabis, CBD, hemp, nootropic, peptide, or any related product, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition. The legal status of these products varies by country, state, and locality; you are solely responsible for verifying and complying with the laws that apply to you. Some listings, reviews, and coupons may be paid placements or affiliate relationships, which do not influence our editorial standards.